{"name":"Celyad Oncology SA","slug":"celyad-oncology-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ENDOXAN","genericName":"ENDOXAN","slug":"endoxan","indication":"Lymphomas (Hodgkin and non-Hodgkin)","status":"phase_3"},{"name":"Fludara","genericName":"Fludara","slug":"fludara","indication":"Acute myeloid leukemia, disease","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Sham, no injection","genericName":"Sham, no injection","slug":"sham-no-injection","indication":"Other","status":"phase_3"},{"name":"C-Cure","genericName":"C-Cure","slug":"c-cure","indication":"Other","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Injection of C3BS-CQR-1","genericName":"Injection of C3BS-CQR-1","slug":"injection-of-c3bs-cqr-1","indication":"Hematologic malignancies (specific indication under investigation in phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"ENDOXAN","genericName":"ENDOXAN","slug":"endoxan","phase":"phase_3","mechanism":"ENDOXAN (cyclophosphamide) is an alkylating agent that cross-links DNA to inhibit cell division and induce apoptosis in rapidly dividing cells.","indications":["Lymphomas (Hodgkin and non-Hodgkin)","Leukemias","Multiple myeloma","Breast cancer","Ovarian cancer"],"catalyst":""},{"name":"Sham, no injection","genericName":"Sham, no injection","slug":"sham-no-injection","phase":"phase_3","mechanism":"This is a sham treatment with no active pharmaceutical ingredient, designed as a control in clinical trials.","indications":[],"catalyst":""},{"name":"C-Cure","genericName":"C-Cure","slug":"c-cure","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Fludara","genericName":"Fludara","slug":"fludara","phase":"marketed","mechanism":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","indications":["Acute myeloid leukemia, disease","Chronic lymphoid leukemia, disease","Low-grade B cell non-Hodgkin lymphoma","Mantle cell lymphoma"],"catalyst":""},{"name":"Injection of C3BS-CQR-1","genericName":"Injection of C3BS-CQR-1","slug":"injection-of-c3bs-cqr-1","phase":"phase_3","mechanism":"C3BS-CQR-1 is an allogeneic CAR-T cell therapy engineered to target and kill cancer cells expressing specific tumor antigens.","indications":["Hematologic malignancies (specific indication under investigation in phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"EIN News","summary":"Allogeneic Cell Therapy Market Size to Hit USD 2.98 Bn by 2032, Driven by Off-the-Shelf Therapies - EIN News","headline":"Allogeneic Cell Therapy Market Size to Hit USD 2.98 Bn by 2032, Driven by Off-the-Shelf Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBZUXFoV1kwaGFVaW9XdHZHanZKRk9RM0kzU0h2LVZyVkI1Mjg3SDU0ald2MERTUkMya1JfakFLQTdRRTdwU2lvUktMZFBURHd1ZEtudWdUaWY1Z29iNlczNDY5YVJRSWJZRGIzeldn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in CYAD (CYAD) - Stock Titan","headline":"If You Invested $1,000 in CYAD (CYAD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOOEloNzBMUVo2VDlxYlpXM2NsZWh0Zmgyb0dZc2dWaXJNUm9adUtqNmdKaWVIWGZnbFJrdWE3bHhZeFlMYkZfc1lpb0N3TXVRQXExTUJaQUZFWFdOTlJOQjhsYkpBM2piWEhJazBwRlpKaUs2YzN0LWFyLW1OUFFSREpRM1IzbklTVkU0Y2RSUHB6TTdnNG0zUGZMVHNnWHhhVlZMRXdwNklETXVwY0tSQ2J3am82VmpRQ2dRX2d6WHh0cGg0TGR4ZEVTb1JGYXNKX2I4S0xBcDFsSWRla1JmaXEzdHdGTVlPcXVXSXJWekRLdUNzQk1VS1YzMVVQVjE2eFZLQjB6Y2JhWFZTbWZXN2l5OFRlOEYxZ3o2ZHFHMkJuMUdZM0ltX3NJRTJSNWVZTWUybThENGFlSWh4ZWc?oc=5","date":"2025-04-23","type":"pipeline","source":"PR Newswire","summary":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire","headline":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQRHVlTHg5NGJWRzRaa2d1UXRha2FEUEthNW9LZmV4dmQ1NHVOU01GcGE4Ulh4amlTUmZqWTFaYTYyOTRCU3ZHM3pwRTZ4MkxRY1cwamt1X3pUd2tUQVRJUEZNUXVhRk5QWWxBbXphLXQ3UWY1STlHZ09ITzEwZVpmRmF0RWw4OTJtckNZNWQ4Y1o4U3ZoZTc2TDJ0a1BTRzVHVEFJX29GTV93QQ?oc=5","date":"2025-03-17","type":"pipeline","source":"The Guardian","summary":"AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’ - The Guardian","headline":"AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOalJtR2w0aVlVUFlGNlo5bEhmT1RxTmRmcm1FV1l0Z0dCQkVrSVN2aWo3dE1ERTBkR00zbzEwWUtGcjFiM2ZTc3NXeHBsbWZEYlU1Qk9QVXpvT21TMy10NlFiWnhXaTh5NXljeVJvalBmMkNBQXpfZzFUWHNJak1FLXlLZHptaGF2M2plZXQ3NjV3cjZLbmVhM3o1Q01CbXRiZFZQTm83Qlcyam93RnBJOFV4ZG9RU3cwZnJZTUhLejdNakZGbFZN?oc=5","date":"2024-10-01","type":"pipeline","source":"PR Newswire","summary":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire","headline":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPUXU5YWpkM3pZZkVGaFdYQ05reG9KYzFtUTlkRmp2LUUwTTE1LU9xanBaZjJtSUhlWjh2bkVhZWJ2WjVVdXhPR0hMbVVYcGl4d2c5cXBianlSa1dGT3ptZENlMnJtN2lheUF6Y1FWQ2Z5VHV5TDVwV3lCd2pBUjIzN0lWSFlLWl95aFBwUGdTZ0c1RGl0Rk5VRFNoTG9vV1BvTk55b25Qd3hwZ0ZKSjBScTFyV1F4d0FBbUxUYVo2TFBEVUhrcmJIMEYwQWlZR0k?oc=5","date":"2024-09-16","type":"pipeline","source":"Business Wire","summary":"Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer - Business Wire","headline":"Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE12QjZOVmhQdGV1WnVMMGo0allRUTVyNThaeXNqaVhVLVNzMnk2Qy0za1p6RVBtQ1VMSy1jSkd3cm9sRnNjb0F1ckZzUHl2UQ?oc=5","date":"2022-10-19","type":"pipeline","source":"Scenari Economici","summary":"Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici","headline":"Le 1001 azioni che si sono schiantate sul mercato azionario USA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNZHVkZFRxdnFCWHRsT1pkQWJieEItSXN2cHp2T0kzSEszMTdJa3JBVkFqMWFjZjJUR3dycWU1b24xM0htUmpRQXRvT01pQm5aaWtRM2tCMTN6RHVtaGpVdnVpc0pNUVJ0RmRGNHF3a2huUzBRSWRzT3ZHZ1oxdjlZVFkyUGZzNmlXQlN2OVJVV3IzTmg0UmFZaXZwMkJWSjcxa2x6WHlaaFpfNzRtWFdOQW9YNjZJbjlveEN1bk1jRHo0cTFkbTdpUkd6bzlLQ2xDMFUzcEpQcERqWmxxRDhYeFp5dEFLUXNELXlsQm82MXZrOTZvQzZtS19R?oc=5","date":"2021-10-06","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight - GlobeNewswire","headline":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight","sentiment":"positive"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}